Hepatitis D

Sherlock's Diseases of the Liver and Biliary System, 12th Edition

Volumn , Issue , 2011, Pages 393-405

  Farci, Patrizia ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Acute hepatitis D; Chronic hepatitis D; Coinfection; HDV RNA; Hepatitis delta virus; Pegylated interferon ; Standard interferon ; Superinfection

Indexed keywords

EID: 79960473787     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341294.ch19     Document Type: Chapter

References (76)

1. Rizzetto M, Canese MG, Aricò S et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18: 997-1003.
2. Rizzetto M, Canese MG, Gerin JL et al. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J. Infect. Dis. 1980; 141: 590-602.
3. Taylor J, Farci P, Purcell RH. Hepatitis D (delta) virus. In: Knipe DM, Howley PM, eds. Fields Virology, 5th edn. Philadelphia: Lippincott, Williams and Wilkins, 2006, p. 3031-3046.
4. Mason WS, Burrell CJ, Casey J et al. Deltavirus. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball AL, eds. Virus Taxonomy, Eighth Report of the International Committee on Taxonomy of Viruses. London: Elsevier/ Academic Press, 2005, p. 735-738.
5. Wang KS, Choo QL, Weiner AJ et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature 1986; 323: 508-514.
6. Glenn JS, Watson JA, Havel CM et al. Identification of a prenylation site in delta virus large antigen. Science 1992; 256: 1331-1333.
7. Shih HH, Jeng KS, Syu WJ et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis D virus. J. Virol. 2008; 82: 2250-2264.
8. Lai MM. RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus. J. Virol. 2005; 79: 7951-7958.
9. Radjef N, Gordien E, Ivaniushina V et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a delta virus genus of at least seven major clades. J. Virol. 2004; 78: 2537-2544.
10. Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr. Top. Microbiol. Immunol. 2006; 307: 151-171.
11. Rizzetto M, Smedile A. Hepatitis D. In: Schiff E, Sorrell M, Maddrey W, eds. Diseases of the Liver. Philadelphia: Lippincott, Williams and Wilkins, 2002, p. 863-875.
12. Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut 1996; 38(Suppl. 2): S48-55.
13. Rizzetto M. Hepatitis D: thirty years after. J. Hepatol 2009; 50: 1043-1050.
14. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection-not a vanishing disease in Europe! Hepatology 2007; 45: 1331-1332.
15. Le Gal F, Castelnau C, Gault E et al. Hepatitis D virus infection-not a vanishing disease in Europe! Reply. Hepatology 2007; 45: 1332-1333.
16. Gaeta GB, Stroffolini T, Smedile A et al. Hepatitis delta in Europe: vanishing or refreshing? Hepatology 2007; 46: 1312-1313.
17. Cross TJ, Rizzi P, Horner M et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J. Med. Virol. 2008; 80: 277-282.
18. Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology 2007; 132: 343-357.
19. Su CW, Huang YH, Huo TI et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-1635.
20. Wu JC. Functional and clinical significance of hepatitis D virus genotype II infection. Curr. Top. Microbiol. Immunol. 2006; 307: 173-186.
21. Casey JL, Brown TL, Colan EJ et al. A genotype of hepatitis D virus that occurs in northern South America. Proc. Natl. Acad. Sci. U S A 1993; 90: 9016-9020.
22. Caredda F, Antinori S, Pastecchia C et al. Incidence of hepatitis delta virus infection in acute HBsAg-negative hepatitis. J. Infect. Dis. 1989; 159: 977-979.
23. Farci P, Smedile A, Lavarini C et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology 1983; 85: 669-673.
24. Smedile A, Farci P, Verme G et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2: 945-947.
25. Farci P, Barbera C, Navone C et al. Infection with the delta agent in children. Gut 1985; 26: 4-7.
26. Bortolotti F, Di Marco V, Vajro P et al. Long-term evolution of chronic delta hepatitis in children. J. Pediatr. 1993; 122: 736-738.
27. Verme G, Amoroso P, Lettieri G et al. A histological study of hepatitis delta virus liver disease. Hepatology 1986; 6: 1303-1307.
28. Buitrago B, Popper H, Hadler SC et al. Specific histologic features of Santa Marta hepatitis: a severe form of hepatitis delta-virus infection in northern South America. Hepatology 1986; 6: 1285-1291.
29. Rizzetto M, Verme G, Recchia S et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann. Intern. Med. 1983; 98: 437-441.
30. Fattovich G, Giustina G, Christensen E et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis(Eurohep). Gut 2000; 46: 420-426.
31. Romeo R, Del Ninno E, Rumi M et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-1638.
32. Rosina F, Conoscitore P, Cuppone R et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999; 117: 161-166.
33. Hadziyannis SJ. Hepatitis delta: an overview. In: Rizzetto M, Purcell RH, Gerin JL et al., eds. Viral Hepatitis and Liver Disease. Torino: Minerva Medica, 1997, p. 283-289.
34. Niro GA, Gravinese E, Martini E et al. Clearance of hepatitis B surface antigen in chronic carriers of hepatitis delta antibodies. Liver 2001; 21: 254-259.
35. Eyster ME, Sanders JC, Battegay M et al. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Dig. Dis. Sci. 1995; 40: 1583-1588.
36. Arribas J, Gonzales-Garcia J, Lorenzo A et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19: 1361-1365.
37. Heidrich B, Deterding K, Tillmann HL et al. Virological and clinical characteristics of delta hepatitis in Central Europe. J. Viral Hepat. 2009; 16: 883-894.
38. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 1101-1108.
39. Lu SN, Chen TM, Lee CM et al. Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. J. Med. Virol. 2003; 70: 74-80.
40. Buti M, Jardi R, Allende H et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J. Med. Virol. 1996; 49: 66-69.
41. Castellares C, Barreiro P, Martín-Carbonero L et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J. Viral Hepat. 2008; 15: 165-172.
42. Roingeard P, Dubois F, Marcellin P et al. Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection. J. Med. Virol. 1992; 38: 191-194.
43. Smedile A, Ciancio A, Rizzetto M. Hepatitis D. In: Richmann DD, Whitley RJ, Hayden FG, eds. Clinical Virology: Hepatitis Delta Virus. Washington DC: ASM Press, 2002, p. 1227-1240.
44. Borghesio E, Rosina F, Smedile A et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 1998; 27: 873-876.
45. Yamashiro T, Nagayama K, Enomoto N et al. Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction, and its possible correlation with the clinical stage of liver disease. J. Infect. Dis. 2004; 189: 1151-1157.
46. Le Gal F, Gordien E, Affolabi D et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J. Clin. Microbiol. 2005; 43: 2363-2369.
47. Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 2006; 44: 536-539.
48. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J. Viral Hepat. 2005; 12: 2-9.
49. Farci P, Mandas A, Coiana A et al. Treatment of chronic hepatitis D with interferon alfa-2a. N. Engl. J. Med. 1994; 330: 88-94.
50. Farci P, Roskams T, Chessa L et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-1749.
51. Battegay M, Simpson LH, Hoofnagle JH et al. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J. Med. Virol. 1994; 44: 389-392.
52. Puoti M, Rossi S, Forleo MA et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J. Hepatol. 1998; 29: 45-52.
53. Weltman MD, Brotodihardjo A, Crewe EB et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J. Viral Hepat. 1995; 2: 39-45.
54. Di Marco V, Giacchino R, Timitilli A et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J. Viral Hepat. 1996; 3: 123-128.
55. Dalekos GN, Galanakis E, Zervou E et al. Interferon-alpha treatment of children with chronic hepatitis D virus infection: the Greek experience. Hepatogastroenterology 2000; 47: 1072-1076.
56. Gunsar F, Akarca US, Ersoz G et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir. Ther. 2005; 10: 721-726.
57. Yurdaydin C, Bozkaya H, Karaaslan H et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J. Viral Hepat. 2007; 14: 812-816.
58. Lau DT, Kleiner DE, Park Y et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999; 117: 1229-1233.
59. Castelnau C, Le Gal F, Ripault MP et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-735.
60. Niro GA, Ciancio A, Gaeta GB et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-720.
61. Erhardt A, Gerlich W, Starke C et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006; 26: 805-810.
62. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 31-40.
63. Kaymakoglu S, Karaca C, Demir K et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob. Agents Chemother. 2005; 49: 1135-1138.
64. Canbakan B, Senturk H, Tabak F et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J. Gastroenterol. Hepatol. 2006; 21: 657-663.
65. Yurdaydin C, Bozkaya H, Onder FO et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J. Viral Hepat. 2008; 15: 314-321.
66. Gaudin JL, Faure P, Godinot H et al. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995; 15: 45-52.
67. Lau DT, Doo E, Park Y et al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30: 546-549.
68. Niro GA, Ciancio A, Tillman HL et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment. Pharmacol. Ther. 2005; 22: 227-232.
69. Yurdaydin C, Bozkaya H, Gürel S et al. Famciclovir treatment of chronic delta hepatitis. J. Hepatol. 2002; 37: 266-271.
70. Manesis EK, Schina M, Le Gal F et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir. Ther. 2007; 12: 381-388.
71. Pugnale P, Pazienza V, Guilloux K et al. Hepatitis delta virus inhibits alpha interferon signaling. Hepatology 2009; 49: 398-406.
72. Glenn JS, Marsters JC Jr, Greenberg HB. Use of a prenylation inhibitor as a novel antiviral agent. J. Virol. 1998; 72: 9303-9306.
73. Bordier BB, Ohkanda J, Liu P et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus (HDV). J. Clin. Invest. 2003; 112: 407-414.
74. Chen TZ, Wu JC, Au LC et al. Specific inhibition of delta antigen by in vitro system by antisense oligodeoxinucleotide: implications for translation mechanism and treatment. J. Virol. Methods 1997; 65: 183-189.
75. Chia JS, Wu HL, Wang HW et al. Inhibition of hepatitis delta virus genomic ribozyme self-cleavage by aminoglycosides. J. Biomed. Sci. 1997; 4: 208-216.
76. Chang J, Taylor JM. Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action. J. Virol. 2003; 77: 9728-9731.